Bausch + Lomb (NYSE:BLCO) PT Lowered to $16.00 at Morgan Stanley

Bausch + Lomb (NYSE:BLCO – Free Report) had its target price cut by Morgan Stanley from $17.00 to $16.00 in a research note issued to investors on Monday, Benzinga reports. They currently have an equal weight rating on the stock. Several other analysts have also recently commented on the company. Evercore ISI assumed coverage on […]

Leave a Reply

Your email address will not be published.

Previous post ImmunoGen (NASDAQ:IMGN) Earns Neutral Rating from Piper Sandler
Next post CVS Group (LON:CVSG) Given Outperform Rating at Royal Bank of Canada